Eli Lilly 2026 Guidance Signals Momentum In Obesity Care
Eli Lilly has forecast 2026 profit and revenue above Wall Street expectations, reinforcing how fast the obesity market is reshaping Big Pharma growth plans. The recent Eli Lilly 2026 Guidance reflects the company’s confidence in strong future performance. The company also beat estimates for fourth-quarter earnings, helped by strong demand for its injectable weight-loss and…...
Lilly’s Orforglipron Shows Significant Weight Loss in Phase 3 Trial
Orforglipron can offer a new oral option for managing weight loss and blood sugar in type 2 diabetes treatment.